Difelikefalin - Cara Therapeutics

Drug Profile

Difelikefalin - Cara Therapeutics

Alternative Names: CKD-943; CR 845; FE 202845; KORSUVA; MR13A9

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Cara Therapeutics; Chong Kun Dang; Maruishi Pharmaceutical
  • Class Opioid analgesics; Peptides
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Pain; Postoperative pain

Highest Development Phases

  • Phase III Postoperative pain; Pruritus
  • Phase II Pain

Most Recent Events

  • 15 Mar 2018 Cara Therapeutics is seeking partnerships and collaborations with companies with expertise in chronic pain to further develop oral difelikefalin for Pain
  • 15 Mar 2018 Cara Therapeutics plans a phase II trial in Pruritus (in patients with CLD-associated pruritus) in 2018 (PO)
  • 15 Mar 2018 Cara Therapeutics plans an international phase III trial for Pruritus (associated with chronic kidney disease) in haemodialysis patients in 2018 (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top